Xinqiao Hospital Of Chongqing
Clinical trials sponsored by Xinqiao Hospital Of Chongqing, explained in plain language.
-
MRNA technology takes on autoimmune diseases in new trial
Disease control Not yet recruitingThis early-phase study tests a new mRNA therapy that targets CD19, a protein on immune cells, to treat autoimmune diseases like lupus and immune anemia. The treatment uses lipid nanoparticles to deliver mRNA that helps the body clear harmful B cells. About 47 participants aged 14…
Phase: EARLY_PHASE1 • Sponsor: Xinqiao Hospital of Chongqing • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New mRNA vaccine trial targets Virus-Linked cancers
Disease control Not yet recruitingThis early-phase trial tests an mRNA immunotherapy for people with tumors linked to the Epstein-Barr virus, such as nasopharyngeal cancer, gastric cancer, and lymphoma. The treatment aims to help the immune system recognize and attack cancer cells. Researchers will check safety a…
Phase: EARLY_PHASE1 • Sponsor: Xinqiao Hospital of Chongqing • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New stroke drug combo aims to boost recovery in Late-Treated patients
Disease control Not yet recruitingThis study tests whether adding the drug eptifibatide after standard clot-dissolving treatment can help people with acute ischemic stroke recover better. It includes 786 adults who arrive at the hospital 4.5 to 24 hours after stroke symptoms start. The goal is to see if this comb…
Phase: PHASE3 • Sponsor: Xinqiao Hospital of Chongqing • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC